Discontinued — last reported Q3 '22
Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 401.6% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$250.00K | -$250.00K | -$250.00K | $0.00 | $15.00M | $0.00 | $0.00 | $64.00M | $0.00 | $0.00 | $0.00 | $0.00 | -$584.00M | $674.00M | $364.00M | $0.00 | $633.00M | $0.00 | $0.00 | $498.00M |
| QoQ Change | — | +0.0% | +0.0% | +100.0% | — | -100.0% | — | — | -100.0% | — | — | — | — | +215.4% | -46.0% | -100.0% | — | -100.0% | — | — |
| YoY Change | — | — | — | — | >999% | +100.0% | +100.0% | — | -100.0% | — | — | -100.0% | — | — | — | — | +208.4% | -100.0% | -100.0% | — |
We use cookies for analytics. See our Privacy and Cookie Policy.